Table 2.

Associations between TDF domains and adoption of chemotherapy across physician specialties for patients with localized muscle-invasive bladder cancer

TDF Domain	Association with “High Adopter”* of Chemotherapy OR (95% CI) *
	Urologists	Medical Oncologists	Radiation Oncologists
Beliefs about consequences	4.87 (1.79–13.26)	2.40 (0.47–12.31)	0.37 (0.06–2.17)
Memory, attention, decision-making skills	0.50 (0.27–0.91)	1.35 (0.52–3.48)	0.66 (0.19–2.24)
Social and professional role	16.50 (4.60–59.16)	4.88 (1.08–22.03)	0.40 (0.09–1.86)
Environmental context and resources	1.65 (0.72–3.77)	1.15 (0.37–3.60)	0.68 (0.22–2.11)
Social influences	5.68 (2.41–13.37)	6.55 (1.50–28.61)	n/a
Behavioural regulation	n/a	12.23 (1.98–75.59)	1.33 (0.74–2.40)
Knowledge	n/a	1.24 (0.62–2.46)	n/a
Beliefs about capabilities	0.53 (0.27–1.03)	1.25 (0.63–2.48)	n/a

*A urologist was defined as a high adopter if they referred a median of≥9/10 MIBC patients to medical oncology for consultation. A medical oncologist was defined as a high adopter if they treated a median of≥7/10 referred MIBC patients with chemotherapy. A radiation oncologist was defined as a high adopter if they referred a median of≥2 of the last 3 patients that they had seen to medical oncology that that were not already referred by urology. OR = odds ratio. CI = confidence interval. n/a = no survey questions for the domain. Bolded values indicate statistically significant results (p < 0.05).